Last reviewed · How we verify
Pentoxifylline, pentaglobin
Pentoxifylline, pentaglobin is a Small molecule drug developed by Zekai Tahir Burak Women's Health Research and Education Hospital. It is currently FDA-approved.
Pentoxifylline is a small molecule that acts as an antagonist of the Adenosine A2 receptor. It is being studied in the treatment of neonatal sepsis, either alone or in combination with pentaglobin, as part of a Phase 4 clinical trial.
At a glance
| Generic name | Pentoxifylline, pentaglobin |
|---|---|
| Sponsor | Zekai Tahir Burak Women's Health Research and Education Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pentoxifylline, pentaglobin CI brief — competitive landscape report
- Pentoxifylline, pentaglobin updates RSS · CI watch RSS
- Zekai Tahir Burak Women's Health Research and Education Hospital portfolio CI
Frequently asked questions about Pentoxifylline, pentaglobin
What is Pentoxifylline, pentaglobin?
Who makes Pentoxifylline, pentaglobin?
What development phase is Pentoxifylline, pentaglobin in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing